Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, both in the development of disease modifying therapies (DMTs) and ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

TOKYO, July 22, 2025 - (JCN Newswire) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced the termination of its engine business operation at Shenyang Aerospace Mitsubishi Motors ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Alzheimer’s disease is a type of dementia, and there are more than 7 million Americans living with it. According to the ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

A growing number of studies have linked midlife mental health disturbances with the development of dementia, but it’s a ...